Abstract

Oscar Health, Inc. will report second‑quarter 2026 results on August 6, 2026 Pre‑Market; this preview outlines consensus expectations for revenue, profitability, and EPS alongside segment dynamics, management’s previously communicated full‑year outlook, and the latest analyst sentiment heading into the print.

Market Forecast

Consensus points to a sharp year‑over‑year acceleration for Oscar Health, Inc. in the current quarter: revenue is estimated at 4.75 billion US dollars, up 64.32%, EBIT is projected at 167.61 million US dollars, up 228.22%, and adjusted EPS is forecast at 0.39, up 183.36%. No company‑specific quarterly guidance for gross margin or net margin has been provided, and we therefore do not include margin forecasts here; the company previously indicated a full‑year 2026 revenue range of 18.70–19.00 billion US dollars, implying continued top‑line expansion into the second half.

The core revenue engine remains premiums before ceded reinsurance, with the company’s prior quarter showing a concentration of revenue in this line and continued emphasis on disciplined underwriting and expense control to sustain profitability. Within non‑premium revenue, technology and services (+Oscar) represents the most promising long‑term monetization avenue; it contributed 5.72 million US dollars last quarter off a small base, and investors will be looking for signs of sequential traction and commercial pipeline conversion.

Last Quarter Review

In the previous quarter (first quarter 2026), Oscar Health, Inc. reported revenue of 4.65 billion US dollars, a gross profit margin of 30.50%, net profit attributable to shareholders of 679.00 million US dollars, a net profit margin of 14.61%, and adjusted EPS of 2.07, up 125.00% year over year. A notable highlight was EBIT of 704.09 million US dollars, up 136.97% year over year, with EPS materially ahead of market expectations while revenue came in modestly below consensus. By business line, premiums before ceded reinsurance generated 4.58 billion US dollars, investment income contributed 60.61 million US dollars, and services and other delivered 5.72 million US dollars; overall revenue grew 52.55% year over year.

Current Quarter Outlook

Core premiums and membership trajectory

With consensus calling for revenue growth of 64.32% year over year, this quarter’s setup implies further expansion in premiums earned and membership contribution within Oscar Health, Inc.’s core book. The first‑quarter mix was dominated by premiums before ceded reinsurance, which amounted to 4.58 billion US dollars; investors will closely track whether second‑quarter run‑rate premiums reflect stable retention and pricing carryover from the January plan year. Management’s focus on underwriting discipline and operating cost control helped deliver a 30.50% gross margin and a 14.61% net margin last quarter; the degree to which these margins normalize as seasonality and utilization shift into the mid‑year months will be a focal point for the quarter.

The core sensitivity for earnings remains medical cost performance relative to pricing and the impact of risk‑adjustment settlements and timing. In the prior quarter, the company converted operating leverage into a 2.07 adjusted EPS print, up 125.00% year over year, underscoring that expense trajectories and claim trend management can translate into disproportionate EPS movement. For this quarter, the EPS estimate of 0.39 embeds lower seasonality‑adjusted profitability than the first quarter, but leaves headroom for upside if loss ratios hold favorably and operating expenses track at or below internal run‑rates.

A related swing factor is the balance between ceded and retained risk. While the revenue line “premiums before ceded reinsurance” dominated Q1, reported profitability depends on the net retained economics post‑reinsurance and the capture of risk‑adjustment transfers. If retained risk remains consistent with internal targets and claims trend remains stable, the 167.61 million US dollars EBIT forecast may prove conservative; conversely, any upward pressure in utilization or one‑time adverse items would likely compress EBIT toward the low end of market expectations.

Technology and services monetization (+Oscar)

Technology and services revenue, captured under “services and other,” was 5.72 million US dollars in the last reported quarter, a small contribution relative to total revenue but one that is margin‑accretive as it scales. Investors will be listening for updates on pipeline conversions, implementation milestones, and the run‑rate cadence of recurring fees, since incremental contributions here can bolster consolidated margin without the volatility associated with medical costs. Because the absolute dollar base is still modest, even a handful of new go‑lives can create noticeable year‑over‑year percentage growth without moving the total revenue needle materially in the near term.

Management continuity and product strategy are also in focus following the transition of the company’s chief technology officer and co‑founder to an advisory role during the second quarter window. Execution around the +Oscar roadmap, client onboarding timelines, and the breadth of the sales funnel will be used by investors as leading indicators of the medium‑term monetization path. From an earnings sensitivity standpoint, a sustained pickup in “services and other” revenue would support a more resilient net margin profile, especially in quarters where insurance operations face seasonally higher medical costs.

The most constructive setup for this quarter is a combination of stable core premiums and incremental growth in technology‑related revenue, reinforcing the multi‑year case for diversified contribution. Any commentary that links +Oscar adoption to operational efficiencies within the insurance platform can also strengthen confidence that expense discipline observed in Q1 can persist, even as consolidated revenue steps higher.

Key stock price drivers around the print

Day‑of‑print share reaction is likely to hinge on the spread between reported results and consensus on revenue and adjusted EPS, and on any refresh to full‑year outlook. Notably, management previously indicated a full‑year 2026 revenue range of 18.70–19.00 billion US dollars; reiteration of that range, paired with a clean in‑line or better second‑quarter EPS versus the 0.39 estimate, would likely be interpreted as confirmation that execution remains on track. Conversely, any indication of higher‑than‑planned medical costs or unexpected one‑time charges could weigh on the implied back‑half earnings trajectory and compress the valuation multiple into the subsequent sessions.

Another near‑term variable is sentiment around leadership changes and insider activity reported during the period. The transition of the chief technology officer to an advisory role and disclosed insider sales have been visible to the market; the extent to which management provides clarity on continuity of the technology roadmap and affirms operating priorities can mitigate concerns that these developments signal a strategic pivot. Clarity on operating expense run‑rate and any incremental efficiencies realized in the second quarter will also be key, because Q1 demonstrated substantial operating leverage with EBIT of 704.09 million US dollars on 4.65 billion US dollars of revenue.

Finally, cadence in non‑premium lines will be scrutinized for incremental margin contribution. Investment income of 60.61 million US dollars last quarter added a smaller but positive contribution to the bottom line; a stable or improved yield backdrop can help cushion volatility in core insurance results. While no explicit margin guidance has been issued for the quarter, investors will triangulate reported net margin and commentary on claims trend against the 14.61% net profit margin delivered in Q1 to assess whether current consensus EPS leaves room for upside.

Analyst Opinions

Bullish views carry the majority among the latest opinions surveyed, with a 2:1 ratio of bullish to bearish ratings within the period reviewed, driven by notable upgrades; neutral/hold views remain prevalent but do not alter the bullish‑to‑bearish ratio. Barclays upgraded the shares to Overweight with a price target of 35 US dollars, citing an improved setup that supports outperformance, and Raymond James upgraded to Outperform, describing the company as the “best house in a tough neighborhood” with an 18 US dollars target at the time of their call. These upgrades, taken together with consensus forecasting revenue up 64.32% and adjusted EPS up 183.36% year over year for the quarter, reflect a constructive stance on the near‑term earnings cadence and on management’s ability to translate top‑line growth into sustained profitability.

The bullish case emphasizes that first‑quarter execution materially exceeded earnings expectations despite a modest revenue shortfall versus consensus, demonstrating operating discipline. With Q1 adjusted EPS of 2.07 up 125.00% year over year and EBIT at 704.09 million US dollars up 136.97%, proponents argue that the bar for second‑quarter EPS of 0.39 leaves potential for an upside surprise if medical costs track favorably. Bulls also point to the previously communicated full‑year revenue range of 18.70–19.00 billion US dollars and look for management to reiterate or refine that outlook, which would validate the trajectory implied by the consensus second‑quarter revenue of 4.75 billion US dollars.

Another pillar of the bullish thesis is incremental improvement in margin quality. Positive contributors include operating expense control—already evident in Q1—and the potential for technology and services revenues to begin adding more visible, higher‑margin dollars. Although “services and other” recorded 5.72 million US dollars in Q1, bulls argue that consistent quarter‑over‑quarter progress serves as a signal of the broader commercialization of the platform and could augment consolidated margins over time. The combination of core premium growth, favorable expense scaling, and a gradually expanding technology and services contribution aligns with the optimistic stance taken by Barclays and Raymond James.

Finally, bullish analysts suggest that the second‑quarter narrative will hinge on confirmation of claim trend stability and the company’s ability to sustain net margins similar to, or slightly below, the 14.61% posted in Q1 given seasonal dynamics. If Oscar Health, Inc. delivers in line or better on revenue and EPS and comments confidently on expense and claims management, the post‑print path for estimates could skew higher, supporting the upgrades that have come through in recent weeks. In short, the majority view expects that operational consistency and disciplined execution will underpin a constructive inflection in both earnings quality and investor sentiment across the remainder of 2026.